Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Portfolio Pulse from Lara Goldstein
PharmaTher Holdings Ltd. has filed a pre-submission facility correspondence for its novel racemic ketamine KETARX to the FDA, aiming for an expedited review. The company expects KETARX approval in Q1 2024 and a U.S. commercial launch in Q2 2024. Meanwhile, mental healthcare treatment provider Stella has acquired Field Trip’s U.S. assets to expand its treatment offerings. The acquisition will allow Stella to assume operations of Field Trip clinics in New York and Washington D.C.
June 27, 2023 | 10:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stella has acquired Field Trip’s U.S. assets, which will allow it to expand its treatment offerings and geographical reach. This could potentially impact Field Trip's stock.
The acquisition of Field Trip’s U.S. assets by Stella could potentially impact Field Trip's stock as it indicates a change in the company's asset base and potential future revenue streams.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PharmaTher has filed for an expedited FDA review of its novel racemic ketamine KETARX, expecting approval in Q1 2024. This could potentially boost the company's stock in the short term.
The filing for an expedited FDA review of KETARX and the expected approval in Q1 2024 could potentially boost PharmaTher's stock as it indicates progress in the company's pipeline and potential future revenue.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100